Cambridge Investment Research Advisors
PRVB

Cambridge Investment Research Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,450
Closed -$686K – 3338
2023
Q1 		$686K Sell
28,450
-1,445
-5% -$18.1K ﹤0.01% 1858
2022
Q4 		$316K Buy
29,895
+13,900
+87% +$112K ﹤0.01% 2392
2022
Q3 		$72K Hold
15,995
– – ﹤0.01% 2908
2022
Q2 		$64K Hold
15,995
– – ﹤0.01% 2924
2022
Q1 		$117K Sell
15,995
-400
-2% -$2.39K ﹤0.01% 2996
2021
Q4 		$92K Sell
16,395
-3,100
-16% -$19.7K ﹤0.01% 3041
2021
Q3 		$125K Buy
19,495
+3,100
+19% +$19.9K ﹤0.01% 2917
2021
Q2 		$138K Sell
16,395
-1,800
-10% -$14.5K ﹤0.01% 2916
2021
Q1 		$191K Buy
18,195
+3,195
+21% +$45K ﹤0.01% 2643
2020
Q4 		$254K Buy
15,000
+400
+3% +$6K ﹤0.01% 2277
2020
Q3 		$187K Sell
14,600
-500
-3% -$6.32K ﹤0.01% 2263
2020
Q2 		$213K Buy
+15,100
New +$191K ﹤0.01% 2134

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cambridge Investment Research Advisors's PRVB Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 28,450 shares — an estimated $686K sold.

Cambridge Investment Research Advisors first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $686K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Cambridge Investment Research Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 28,450 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $686K.
  • Cambridge Investment Research Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Cambridge Investment Research Advisors's Provention Bio, Inc. Common Stock position peaked at $686K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.